Company Encyclopedia
View More
name
Cochlear Limited
CHEOY.US
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
1.391 T
CHEOY.USMarket value -Rank by Market Cap -/-

Financial Score

17/11/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking15/170
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE20.52%A
    • Profit Margin16.60%A
    • Gross Margin73.74%A
  • Growth ScoreC
    • Revenue YoY2.60%C
    • Net Profit YoY6.70%C
    • Total Assets YoY0.67%C
    • Net Assets YoY3.66%C
  • Cash ScoreC
    • Cash Flow Margin602.49%C
    • OCF YoY2.60%C
  • Operating ScoreB
    • Turnover0.84B
  • Debt ScoreB
    • Gearing Ratio30.96%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Cochlear Limited’s Innovative Study on Speech Perception Using Mobile App

    Cochlear Limited is conducting a study titled ‘A Prospective, Repeated-measures Investigation to Validate Digital Speech Perception Endpoints in Adult Cochlear Implant Recipients Using the Mobile Research App.’ The study aims to validate speech perception assessments for adults with cochlear implants using a mobile app, enhancing understanding and management of hearing loss. It tests the Mobile Research App (MRA) for flexible testing. The study began on October 19, 2023, and is recruiting participants, with completion expected by April 27, 2025. This innovation may positively impact Cochlear Limited’s stock performance and investor sentiment.

    Tip Ranks·
    US
    CHEOY
    +0.37%
    Tip Ranks·
    US
    CHEOY
    +0.37%

    Cochlear Reaffirms Fiscal 2026 Underlying Profit Guidance

    Cochlear Reaffirms Fiscal 2026 Underlying Profit Guidance

    marketscreener·
    US
    CHEOY
    +0.37%
    marketscreener·
    US
    CHEOY
    +0.37%

    Cautious Outlook on Cochlear: Sell Rating Due to FY26 NPAT Reliance and Nexa Implant Uncertainty

    David Bailey has issued a Sell rating on Cochlear due to concerns over its FY26 net profit after tax (NPAT) guidance, which heavily relies on the anticipated launch of the Nexa implant. Uncertainty regarding the implant's market uptake and Morgan Stanley's forecasts indicating potential underperformance in NPAT compared to expectations raise doubts about Cochlear's ability to meet full-year guidance. Bailey, a 4-star analyst, focuses on the Healthcare sector and has an average return of 13.9% with a 46.97% success rate.

    Tip Ranks·
    US
    CHEOY
    +0.37%
    Tip Ranks·
    US
    CHEOY
    +0.37%

    Does Cochlear (ASX:COH) Deserve A Spot On Your Watchlist?

    Cochlear (ASX:COH) is gaining attention as a potential investment due to its consistent earnings growth, with EPS increasing by 11% annually over the past three years. The company also reported a 4.8% revenue growth to AU$2.3 billion while maintaining stable EBIT margins. Insider buying, totaling AU$201k, indicates confidence in the company's future, particularly from Non-Executive Director Caroline Clarke. Additionally, CEO compensation is modest compared to peers, suggesting good governance. Overall, Cochlear's profitability and insider confidence make it a candidate for investors' watchlists.

    Simplywall·
    US
    CHEOY
    +0.37%
    Simplywall·
    US
    CHEOY
    +0.37%

    Canaccord Genuity Reaffirms Their Hold Rating on Cochlear (CHEOF)

    In addition to Canaccord Genuity, Cochlear also received a Hold from Citi’s Laura Sutcliffe in a report issued on September 18. However, on September 26, Morgan Stanley maintained a Sell rating on Cochlear (Other OTC: CHEOF).

    Tip Ranks·
    US
    CHEOY
    +0.37%
    Tip Ranks·
    US
    CHEOY
    +0.37%